Next Article in Journal
WB1, a Regulator of Endosperm Development in Rice, Is Identified by a Modified MutMap Method
Next Article in Special Issue
Regulation of Energy Metabolism during Early B Lymphocyte Development
Previous Article in Journal
Effects of Funneliformis mosseae on Root Metabolites and Rhizosphere Soil Properties to Continuously-Cropped Soybean in the Potted-Experiments
Previous Article in Special Issue
The Making of Hematopoiesis: Developmental Ancestry and Environmental Nurture
Open AccessArticle

Mining the Plasma Cell Transcriptome for Novel Cell Surface Proteins

The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia
Department of Medical Biology, University of Melbourne, Parkville, VIC 3010 Australia
CSL Limited, Parkville, VIC 3010, Australia
Haematology Department, Monash Health, Clayton, VIC 3168, Australia
Department of Clinical Haematology, Alfred Health, Melbourne 3004, Australia
Australian Centre for Blood Diseases, Monash University, Melbourne 3004, Australia
Department of Computing and Information Systems, University of Melbourne, Parkville, VIC 3010, Australia
Author to whom correspondence should be addressed.
These authors contributed equally to this study.
Int. J. Mol. Sci. 2018, 19(8), 2161;
Received: 28 June 2018 / Revised: 20 July 2018 / Accepted: 20 July 2018 / Published: 24 July 2018
Antibody Secreting Cells (ASCs) are a fundamental component of humoral immunity, however, deregulated or excessive antibody production contributes to the pathology of autoimmune diseases, while transformation of ASCs results in the malignancy Multiple Myeloma (MM). Despite substantial recent improvements in treating these conditions, there is as yet no widely used ASC-specific therapeutic approach, highlighting a critical need to identify novel methods of targeting normal and malignant ASCs. Surface molecules specifically expressed by the target cell population represent ideal candidates for a monoclonal antibody-based therapy. By interrogating the ASC gene signature that we previously defined we identified three surface proteins, Plpp5, Clptm1l and Itm2c, which represent potential targets for novel MM treatments. Plpp5, Clptm1l and Itm2c are highly and selectively expressed by mouse and human ASCs as well as MM cells. To investigate the function of these proteins within the humoral immune system we have generated three novel mouse strains, each carrying a loss-of-function mutation in either Plpp5, Clptm1l or Itm2c. Through analysis of these novel strains, we have shown that Plpp5, Clptm1l and Itm2c are dispensable for the development, maturation and differentiation of B-lymphocytes, and for the production of antibodies by ASCs. As adult mice lacking either protein showed no apparent disease phenotypes, it is likely that targeting these molecules on ASCs will have minimal on-target adverse effects. View Full-Text
Keywords: plasma cell; antibody; CLPTM1L; ITM2C; PLPP5; membrane protein plasma cell; antibody; CLPTM1L; ITM2C; PLPP5; membrane protein
Show Figures

Graphical abstract

MDPI and ACS Style

Trezise, S.; Karnowski, A.; Fedele, P.L.; Mithraprabhu, S.; Liao, Y.; D’Costa, K.; Kueh, A.J.; Hardy, M.P.; Owczarek, C.M.; Herold, M.J.; Spencer, A.; Shi, W.; Willis, S.N.; Nutt, S.L.; Corcoran, L.M. Mining the Plasma Cell Transcriptome for Novel Cell Surface Proteins. Int. J. Mol. Sci. 2018, 19, 2161.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop